Browsing by Autor "Colin Forsyth"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • Thumbnail Image
    Item type: Item ,
    Clinical use of molecular methods for Trypanosoma cruzi infection in endemic and non-endemic countries: Benefits, limitations and challenges
    (Frontiers Media, 2023) María‐Jesús Pinazo; Colin Forsyth; Constanza Lopez-Albízu; Margarita Bisio; Adriana González Martínez; Laura C. Bohórquez; Jimy Pinto; Israel Molina; Andrea Marchiol; Rafael Herazo
    <i>Trypanosoma cruzi</i> infection is diagnosed by parasitological, molecular, and serological tests. Molecular methods based on DNA amplification provide a more sensitive alternative to classical parasitological techniques for detecting evidence of <i>T. cruzi</i> parasitemia, and are the preferred tests for congenital and oral transmission cases and parasite reactivation in chronically infected immunosuppressed individuals. In newborns at risk of vertical transmission, simplified diagnostic algorithms that provide timely results can reduce the high follow-up losses observed with current algorithms. Molecular methods have also proved useful for monitoring <i>T. cruzi</i> infection in solid organ transplantation recipients, regardless of host immune status, allowing parasite detection even before symptom manifestation. Furthermore, in the absence of other biomarkers and a practical test of cure, and given the limitations of serological methods, recent clinical guidelines have included polymerase chain reaction (PCR) to detect therapeutic failure after antiparasitic treatment in chronically infected adults. Increasing evidence supports the use of molecular tests in a clinical context, given the improved sensitivity and specificity of current assays - characteristics which largely depend on epidemiological factors and genetic and antigenic variability among <i>T. cruzi</i> strains. Further development and registration of commercial PCR kits will improve the use of molecular tests. We discuss the attributes of PCR and other molecular tests for clinical management in people with <i>T. cruzi</i> infection.
  • Thumbnail Image
    Item type: Item ,
    Interventions to bring comprehensive care to people with Chagas disease: Experiences in Bolivia, Argentina and Colombia
    (Elsevier BV, 2019) María‐Jesús Pinazo; Ana Cristina Pereiro; Rafael Herazo; Marina Chopita; Colin Forsyth; Mabel Lenardón; Irene Losada; Faustino Torrico; Andrea Marchiol; Mauricio Vera
    Chagas disease (CD) affects over six million people and is a leading cause of heart failure in the Americas. Few are able to access diagnosis and treatment for CD, resulting in a missed opportunity to prevent morbimortality. Integration of testing and treatment with the primary healthcare level is a key step in ensuring affected people receive timely antitrypansomal therapy, which increasing evidence shows can prevent chronic complications from the disease and halt congenital transmission. This article describes three collaborative projects focused on increasing access to testing and treatment for CD through primary healthcare facilities in Bolivia, Argentina, and Colombia.
  • Thumbnail Image
    Item type: Item ,
    New regimens of benznidazole for the treatment of chronic Chagas disease in adult participants in indeterminate form or with mild cardiac progression (NuestroBen study): protocol for a phase III randomised, multicentre non-inferiority clinical trial
    (BMJ, 2025) Tayná Marques; Colin Forsyth; Fabiana Barreira; Carola Lombas; B Oliveira; Mónica Laserna; Israel Molina; María del Carmen Bangher; Rosa Martí Fernández; Susana Lloveras
    NCT04897516.
  • Thumbnail Image
    Item type: Item ,
    Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection
    (Public Library of Science, 2026) Colin Forsyth; Facundo Garcia-Bournissen; Guillermo Moscatelli; Samanta Moroni; Ana Cristina Pereiro; Lourdes Ortiz-Daza; Elvira-Idalia Hernández Cuevas; Freddy Tinajeros; Tayná Marques; Andrea Marchiol
    The TPP provides guidance for essential and ideal characteristics of formulations of new drugs for the treatment of children with T. cruzi infection.